Pharmaceutical News

RSS

Baylor Endocrine Center seeks volunteers to compare long-term benefits and risks of diabetes drugs

Baylor Endocrine Center is looking for volunteers to take part in a study to compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating type 2 diabetes. The project is called the GRADE: Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study.

4 Jun 2013

Report: 83% of cancer doctors face oncology drug shortages

Eighty-three percent of cancer doctors report that they've faced oncology drug shortages, and of those, nearly all say that their patients' treatment has been impacted, according to a study from researchers at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 2013 annual meeting of the American Society of Clinical Oncology (Abstract #CRA6510).

4 Jun 2013

Using cholesterol-lowering statins may be associated with musculoskeletal conditions

Using cholesterol-lowering statins may be associated with musculoskeletal conditions, arthropathies (joint diseases) and injuries, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.

4 Jun 2013

Soligenix receives FDA Fast Track designation for SGX942 to treat patients with oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company, announced today that its SGX942 development program for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in head and neck cancer patients has received "Fast Track" designation from the US Food and Drug Administration.

3 Jun 2013

NeuroDerm receives MJFF grant to develop ND0612 for treatment of Parkinson's disease

NeuroDerm, Ltd. was informed today that it was awarded, for the second time, a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research to support the clinical development of its subcutaneously delivered drug for the treatment of Parkinson's disease.

3 Jun 2013

New drug shows promising results with manageable side effects for treating melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.

3 Jun 2013

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

3 Jun 2013

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.

3 Jun 2013

Study: GLT1 protein plays a critical role in cocaine craving

A new study conducted by a team of Indiana University neuroscientists demonstrates that GLT1, a protein that clears glutamate from the brain, plays a critical role in the craving for cocaine that develops after only several days of cocaine use.

3 Jun 2013

Human tumors with MET amplification respond to MET inhibitor drugs

A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research.

3 Jun 2013

Twitter: A popular source for receiving and sharing new information about vaccines

Twitter is a popular source for receiving and sharing new information about vaccines, and also a basically reliable one, according to a study published in the June issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).

1 Jun 2013

Concerns raised about popular blood pressure, diabetes drugs

The Wall Street Journal reports that a senior FDA regulator is seeking stronger warnings about a class of blood pressure drugs that may be linked to higher cancer rates. Meanwhile, The New York Times details how a doctor hired by Merck to test a diabetes drug in rats found a possible link to pancreatic cancer, a discovery that turned the doctor into a crusader.

1 Jun 2013

New paper analytical devices can screen fake antimalarial drugs

On Wednesday, 5/29/13, the Wall Street Journal published an article titled "Africa's Malaria Battle: Fake Drug Pipeline Undercuts Progress." The piece outlines a counterfeit pharmaceutical problem that is top of mind at Saint Mary's College in Notre Dame, IN. Chemistry Professor Toni Barstis and her undergraduate students at this Catholic, women's, liberal arts college have researched and developed Paper Analytical Devices (PADs) that can screen whether an antimalarial drug is real.

1 Jun 2013

Elderly patients exposed to general anaesthesia face increased risk of developing dementia

Exposure to general anaesthesia increases the risk of dementia in the elderly by 35%, says new research presented at Euroanaesthesia, the annual congress of the European Society of Anaesthesiology (ESA). The research is by Dr Francois Sztark, INSERM and University of Bordeaux, France, and colleagues.

1 Jun 2013

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

A new partnership, first of its kind for both organizations, will see Roswell Park Cancer Institute and Jasco Pharmaceuticals, LLC collaborating to advance development of an investigational pharmacological therapy that shows promise for treating both solid-tumor cancers and hematologic malignancies.

1 Jun 2013

New drug for multiple myeloma could be available within next few months in Europe

The International Myeloma Foundation - improving the quality of life of myeloma patients while working toward prevention and a cure - today said the newest drug for treating multiple myeloma could be available to patients in Europe within the next few months.

1 Jun 2013

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Many glioblastoma patients treated with bevacizumab (Avastin-) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center.

1 Jun 2013

Depomed receives complete response letter for SEFELSA NDA

Depomed, Inc., a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration issued a complete response letter to the New Drug Application for SEFELSA, Depomed's investigational, oral, twice daily formulation of gabapentin to treat moderate to severe vasomotor symptoms due to menopause.

1 Jun 2013

Only one-fifth of RA patients had overall adherence rate to prescribed oral medications, study finds

A new study conducted in an ethnically diverse and predominantly low income population found that only one-fifth of rheumatoid arthritis patients had an overall adherence rate to prescribed oral medications at 80% or greater.

1 Jun 2013

GLYX-13 drug induces antidepressant results without street drug side effects

GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects, reported a study funded by the National Institute of Mental Health (NIMH) that was published last month in Neuropsychopharmacology.

31 May 2013

Pharmaceutical News

Baylor Endocrine Center seeks volunteers to compare long-term benefits and risks of diabetes drugs

Report: 83% of cancer doctors face oncology drug shortages

Using cholesterol-lowering statins may be associated with musculoskeletal conditions

Soligenix receives FDA Fast Track designation for SGX942 to treat patients with oral mucositis

NeuroDerm receives MJFF grant to develop ND0612 for treatment of Parkinson's disease

New drug shows promising results with manageable side effects for treating melanoma

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

Study: GLT1 protein plays a critical role in cocaine craving

Human tumors with MET amplification respond to MET inhibitor drugs

Twitter: A popular source for receiving and sharing new information about vaccines

Concerns raised about popular blood pressure, diabetes drugs

New paper analytical devices can screen fake antimalarial drugs

Elderly patients exposed to general anaesthesia face increased risk of developing dementia

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

New drug for multiple myeloma could be available within next few months in Europe

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Depomed receives complete response letter for SEFELSA NDA

Only one-fifth of RA patients had overall adherence rate to prescribed oral medications, study finds

GLYX-13 drug induces antidepressant results without street drug side effects

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News